|
Zileuton as a chemopreventive agent for chronic myeloid leukemia
|
1R01CA176179-01A1
|
$347,563
|
$347,563
|
LI, SHAOGUANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S1
|
$75,000
|
$3,000
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S2
|
$333,000
|
$13,320
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S3
|
$200,000
|
$8,000
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
3P30CA016359-35S4
|
$150,000
|
$6,000
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Yale Comprehensive Cancer Center Support Grant
|
5P30CA016359-35
|
$2,522,007
|
$100,880
|
LYNCH, THOMAS
|
YALE UNIVERSITY
|
|
Vitamin D Analogs as Adjuvants in Chemotherapy of Cancer
|
5R01CA044722-24
|
$216,873
|
$108,437
|
STUDZINSKI, GEORGE
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
Validation of microRNAs as therapeutic targets in hematological malignancies
|
5R01CA135332-04
|
$306,945
|
$153,473
|
MARCUCCI, GUIDO
|
OHIO STATE UNIVERSITY
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S1
|
$74,856
|
$1,497
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S2
|
$122,401
|
$2,448
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-40S3
|
$150,000
|
$3,000
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-40
|
$4,421,130
|
$88,423
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
University of Maryland Greenebaum Cancer Center Support Grant
|
3P30CA134274-07S1
|
$355,196
|
$17,760
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Maryland Greenebaum Cancer Center Support Grant
|
5P30CA134274-07
|
$1,535,000
|
$76,750
|
CULLEN, KEVIN
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
University of Kentucky Markey Cancer Center - Cancer Center Support Grant
|
3P30CA177558-02S1
|
$75,000
|
$3,750
|
EVERS, BERNARD
|
UNIVERSITY OF KENTUCKY
|
|
University of Kentucky Markey Cancer Center - Cancer Center Support Grant
|
3P30CA177558-02S2
|
$150,000
|
$7,500
|
EVERS, BERNARD
|
UNIVERSITY OF KENTUCKY
|
|
University of Kentucky Markey Cancer Center - Cancer Center Support Grant
|
5P30CA177558-02
|
$1,500,000
|
$75,000
|
EVERS, BERNARD
|
UNIVERSITY OF KENTUCKY
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-18S3
|
$1,211,843
|
$72,711
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-18S4
|
$73,445
|
$4,407
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
Understanding Hemotopoietic Neoplasias using Humanized Mice
|
5R01CA156689-05
|
$470,918
|
$470,918
|
FLAVELL, RICHARD
|
YALE UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-15S1
|
$73,216
|
$2,929
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
5P30CA056036-15
|
$2,723,515
|
$108,941
|
PESTELL, RICHARD
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Investigation of KRas & NF1 in Myeloid Leukemia
|
5R37CA072614-18
|
$295,630
|
$295,630
|
SHANNON, KEVIN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Transcription and Splicing Dynamics in Single Cells
|
ZIA BC 011383
|
$762,476
|
$76,248
|
Larson, Daniel
|
CCR (NCI)
|
|
TOWARD AN UNDERSTANDING OF CLL PROGRESSION
|
5R01CA151319-04
|
$363,375
|
$363,375
|
CROCE, CARLO
|
OHIO STATE UNIVERSITY
|
|
Therapeutic Targeting of Leukemia-Microenvironmental Interactions
|
5R01CA166280-02
|
$308,958
|
$308,958
|
CALVI, LAURA
|
UNIVERSITY OF ROCHESTER
|
|
The Therapy of CML
|
5P01CA049639-24
|
$3,477,908
|
$3,477,908
|
CHAMPLIN, RICHARD
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The Role of the APC Tumor Suppressor Gene in Hematopoiesis and Leukemogenesis
|
5R01CA140979-05
|
$316,002
|
$316,002
|
QIAN, ZHIJIAN
|
UNIVERSITY OF ILLINOIS AT CHICAGO
|
|
The Role of Telomere Shortening in MDS-AML Pathogenesis (resubmission)
|
5R01CA160433-03
|
$326,066
|
$326,066
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
The role of ICSBP in the pathogenesis of chronic myeloid leukemia
|
5R01CA174205-02
|
$310,970
|
$310,970
|
EKLUND, ELIZABETH
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Role of EglN1 and HIF in Normal Hematopoiesis and in Leukemia
|
1K99CA181488-01
|
$176,720
|
$176,720
|
LOSMAN, JULIE
|
DANA-FARBER CANCER INST
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-19S3
|
$21,615
|
$1,513
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-20S1
|
$75,000
|
$5,250
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-20S2
|
$50,000
|
$3,500
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-20S3
|
$77,097
|
$5,397
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-20
|
$4,686,132
|
$328,029
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Targeting the C/EBPalpha-Gfi-pathway in CML stem cells
|
5R01CA167169-02
|
$311,976
|
$311,976
|
CALABRETTA, BRUNO
|
THOMAS JEFFERSON UNIVERSITY
|
|
Targeting PML for therapy in leukemia-initiating cells
|
5R00CA139009-05
|
$241,530
|
$241,530
|
ITO, KEISUKE
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Targeting PML for leukemia therapy.
|
5R01CA142874-05
|
$436,776
|
$436,776
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Targeting BCL6 in tyrosine kinase-driven leukemia
|
5R01CA169458-02
|
$317,679
|
$158,840
|
MUSCHEN, MARKUS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-04
|
$307,951
|
$307,951
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
T cell repertoire of graft-versus-host disease and graft-versus-tumor effects
|
5R01CA154244-10
|
$376,976
|
$376,976
|
KORNGOLD, ROBERT
|
HACKENSACK UNIVERSITY MEDICAL CENTER
|
|
Systems Biology of Diversity in Cancer
|
5U54CA148967-05
|
$2,815,894
|
$309,748
|
SANDER, CHRIS
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Suppression of BCR-ABL by siRNA-loaded Nanoparticles for the Treatment of CML
|
5F31CA174298-02
|
$42,676
|
$42,676
|
GAVRILOV, KSENIYA
|
YALE UNIVERSITY
|
|
Study of the Roles of SDF1 and CXCR4 in Hematopoiesis
|
ZIA BC 010782
|
$338,567
|
$84,642
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Studies of BCR-ABL leukemogenesis in mice
|
7R01CA090576-14
|
$266,107
|
$266,107
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
Stopping Tyrosine Kinase Inhibitors in CML Patients (Stop-TKIs)
|
1R01CA184798-01A1
|
$785,520
|
$785,520
|
ATALLAH, EHAB
|
MEDICAL COLLEGE OF WISCONSIN
|
|
Statistical analysis methods for validating risk prediction models
|
1R21CA185704-01
|
$225,765
|
$112,883
|
UNO, HAJIME
|
DANA-FARBER CANCER INST
|
|
Stanford University Cancer Center
|
3P30CA124435-08S1
|
$75,000
|
$750
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
Stanford University Cancer Center
|
3P30CA124435-08S2
|
$323,044
|
$3,230
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
Total relevant funding to Chronic Myeloproliferative Disorders for this search: $36,747,316
|